Solventum (SOLV) FY2025 results: revenue $8.3 billion, up 0.9% on the year

Solventum develops, manufactures and sells healthcare products that draw on material science, data science and digital capability. Its products sit along a patient's journey through prevention, diagnosis, treatment and recovery, and its customers run from multidisciplinary hospitals to local clinics and practices. The company points to a history of more than 70 years of discovering and developing its solutions; it became a separate company through a spin-off from 3M, and continues to use 3M's distribution networks and manufacturing sites under a Transition and Distribution Agreement and a Transition Contract Manufacturing Agreement while it builds its own. It employs approximately 20,000 people, approximately 10,000 of them in the United States and approximately 2,000 in Germany, with approximately 4,000 working in plants; approximately 40% have more than ten years of tenure.

Three segments

MedSurg, 57.9% of 2025 total sales, covers negative pressure wound therapy, advanced wound dressings, advanced skin care, synthetic tissue matrices, intravenous site management, sterilisation assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes and medical technologies made for other equipment manufacturers. The stated purpose is to speed healing, prevent complications and lower the total cost of care, with the surgical range aimed at reducing a patient's risk of infection or complication.

Health Information Systems, 16.3% of 2025 total sales, is software for healthcare systems: computer-assisted physician documentation, direct-to-bill and coding automation, classification methodologies, speech recognition and data visualisation. It is aimed at cutting waste out of the revenue cycle, freeing clinician time and supporting value-based care, with accuracy of reimbursement and a lighter administrative load as the stated objectives.

Dental Solutions, 16.2% of 2025 total sales, covers dental and orthodontic products including brackets, aligners, restorative cements and bonding agents, spanning what the company calls the life of the tooth, from preventative care through direct and indirect restoration to orthodontics.

How it sells

There are sales in over 90 countries, reached through several models at once: direct to customer, distribution, key account management, inside sales and e-commerce. Marketing covers brand management, insights, price management, digital marketing and integrated communications. Behind the sale sit service support teams: clinical specialists who are licensed nurses or technicians, medical liaisons who are clinical professionals such as surgeons and dentists, and application engineers who are technical specialists, each acting as the clinical or technical expert for the customer.

In emerging geographies across Latin America, Europe, the Middle East and Africa, and Asia, the company uses an export model instead, relying on local partners to market and sell, to handle regulatory and cross-border import compliance and to distribute directly to the customer, with its own export commercial team supplying technical, clinical and marketing support both to customers and to those partners.

Portfolio changes in 2025

The company acquired Acera Surgical, a privately held bioscience company, and sold its Purification and Filtration business to Thermo Fisher Scientific. It states that it intends to keep monitoring its portfolio and organisational structure and may make further acquisitions and divestitures.

From Solventum's annual report on Form 10-K for the year ended 31 December 2025. The filing

Written from the 10-K filed 27 February 2026: read the full 10-K.